|
Genotype distributions of VKORC1 1173 C>T, CYP2C9*2 and CYP2C9*3 polymorphisms in the investigated patients (MAF = minor allele frequency). |
||||||||
| Genotype |
Total material N = 212 |
Warfarin N = 58 |
ASA N = 72 |
Warfarin + ASA N = 47 |
||||
|
|
||||||||
| Number of patients (genotype frequency in %) |
MAF (%) |
Number of patients (genotype frequency in %) |
MAF (%) |
Number of patients (genotype frequency in %) |
MAF (%) |
Number of Patients (genotype Frequency in %) |
MAF (%) |
|
|
|
||||||||
| VKORC1 |
||||||||
| 1173 C>T |
36.6 |
40.5 |
36.1 |
33.0 |
||||
| CC |
85 (40.1) |
20 (34.5) |
30 (41.7) |
23 (48.9) |
||||
| CT |
99 (46.7) |
29 (50.0) |
32 (44.4) |
17 (36.2) |
||||
| TT |
28 (13.2) |
9 (15.5) |
10 (13.9) |
7 (14.9) |
||||
| CYP2C9 |
||||||||
| *1/*1 |
147 (69.3) |
40 (69.0) |
48 (66.7) |
33 (70.2) |
||||
| *1/*2 |
38 (17.9) |
11.3 |
12 (20.7) |
11.2 |
10 (13.9) |
7.6 |
8 (17.0) |
17.0 |
| *2/*2 |
4 (1.9) |
- |
- |
4 (8.5) |
||||
| *1/*3 |
20 (9.4) |
5.7 |
5 (8.6) |
5.2 |
12 (16.7) |
10.4 |
2 (4.3) |
2.1 |
| *3/*3 |
1 (0.5) |
- |
1 (1.4) |
- |
||||
| *2/*3 |
2 (0.9) |
1 (1.7) |
1 (1.4) |
- |
||||
Haug et al. Thrombosis Journal 2008 6:7 doi:10.1186/1477-9560-6-7 |
||||||||